Anthropic, the artificial intelligence company behind the Claude chatbot, has announced it will begin an internal drug discovery program focused on neglected diseases that traditional pharmaceutical companies often overlook. The move marks the latest bet by a major tech firm on the healthcare sector, but with a specific emphasis on conditions that lack commercial incentives for drug development.
At an event in San Francisco, Eric Kauderer-Abrams, Anthropic’s head of life sciences, said the company will use its AI models to identify potential treatments for diseases that “traditional biopharmaceutical companies wouldn’t consider attractive targets.” The initiative is part of a broader effort to build and refine AI tools for drugmakers, including the company’s new product Claude Science. “We believe in the power of tight feedback loops, and there’s no substitute for having our own experiences alongside you all in the trenches trying to develop drugs,” Kauderer-Abrams told the audience.
The company has positioned itself as a public benefit corporation, which allows it to prioritize patient need over profit. An Anthropic spokesperson said the firm “can choose programs on patient benefit, including work the commercial market overlooks.” While Kauderer-Abrams did not specify what would happen if the program identifies promising drug candidates, traditional biopharma companies would typically test such candidates in clinical trials. Anthropic said it is “at the start of this” and will share more details as the work progresses.
Tech Giants and Healthcare: A Mixed Track Record
Anthropic joins a long line of technology companies aiming to break into healthcare, a sector that has proven difficult to disrupt. Alphabet and Apple have made various forays into health data and wearables, while Amazon has built a healthcare division called Amazon Health Services through acquisitions of One Medical and PillPack. Anthropic’s approach differs by focusing on diseases that lack commercial appeal, such as rare or tropical illnesses that affect smaller patient populations.
Jonah Cool, Anthropic’s head of life sciences partnerships, emphasized that the company’s goal is to work alongside the drugmakers it hopes to serve. By investing in its own drug discovery program, Anthropic aims to better understand the challenges its customers face. “There’s no substitute for having our own experiences,” Kauderer-Abrams said, signaling that the company intends to learn by doing rather than simply selling tools from the outside.
Looking ahead, Anthropic says it will continue to develop AI models tailored for life sciences while exploring how its internal discoveries might eventually reach patients. The company has not set a timeline for clinical trials or regulatory filings, but leaders expressed optimism that the effort could open new avenues for treating diseases that have long been neglected by the pharmaceutical industry.